Skip to content Skip to footer
Autoimmune diseases

Science

Autoimmune diseases

Our focus is to develop innovative therapies to treat autoimmune diseases where the body’s natural immune system mistakenly attacks normal healthy cells. Autoimmune diseases affect a wide range of organs that can have a profound effect on human health. There are over 100 known autoimmune diseases where, in many cases, women are disproportionally affected.

Promising research

Demyelinating diseases

Many demyelinating diseases are inflammatory autoimmune diseases where the body’s own immune system attacks and destroys the myelin sheaths that envelop and support axons in the central nervous system.

Chronic Optic Neuropathy is the result of chronic, progressive myelin damage of the optic nerve and visual tracts in the brain.

In central nervous system inflammatory diseases, such as Multiple Sclerosis (MS), autoimmune reactions cause inflammation leading to destruction of myelin and myelinated axons in the visual pathway, resulting in chronic visual impairment and loss of quality of life. Two forms of visual impairment associated with MS are Acute Optic Neuritis (AON) and Chronic Optic Neuropathy (CON).

Many people with MS, will experience attacks of AON, characterized by subacute onset of pain and diminished vision, usually in one eye. Acute optic neuritis is often treated with corticosteroids and most people recover from individual attacks within a few months. CON on the other hand, is a more debilitating condition characterized by serious visual impairment, with irreversible loss of vision. CON does not respond to corticosteroid or disease modifying immunomodulatory MS treatment. There is a major unmet medical need to find safe and effective treatments that can repair damaged myelin in the optic nerve and visual tracts of the brain to preserve axonal function and restore vision in CON.

Up to 50% of people with MS will experience an episode of optic neuritis during the course of their disease. In the United States, there are an estimated prevalence of 90,000 people who suffer from Chronic Optic Neuropathy.

There are other forms of Optic Neuropathy that are distinct from CON and AON. These include Neuromyelitis Optica (NMO) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) that also involve loss of myelin in the optic nerve due to specific inappropriate auto-immune responses leading to destruction of central nervous system myelin. These are rare chronic diseases that can lead to worsening of vision until blindness. NMO and MOGAD each have a prevalence of approximately 10,000 people in the United States.

Safe and effective therapies that promote repair of myelin are urgently needed.

Although numerous immunomodulatory drugs modulating the immune and inflammatory components of MS have been approved over the past 20 years, there is a major unmet need for drugs that can repair myelin in people with CON and other demyelinating diseases such as MS.

We are developing remyelinating agents to repair and rebuild myelin

We are developing novel remyelinating agents that target a transmembrane receptor complex located on oligodendrocytes which regulates myelin formation in the CNS. When the receptor complex is activated, it blocks migration to areas of damage and remyelination by oligodendrocytes. Our remyelinating agents are designed to disrupt the receptor complex and remove the barriers to remyelination.

Our lead molecule (FTX-101) is a peptide that targets the transmembrane region of this receptor to promote remyelination. FTX-101 has completed IND-enabling studies and is expected to enter Phase 1 clinical studies at the beginning of 2024.

Promising research

Diseases of
the GI tract

We have identified certain GPCRs that are involved in autoimmune diseases of the GI tract with a significant unmet need.

GPCRs are the largest and most diverse superfamily of membrane receptors that mediate most of our physiological responses to hormones, neurotransmitters, and environmental stimulants. They are characterized by seven transmembrane domains and activate associated G proteins responsible for intracellular signaling. It has been estimated that 30% of all FDA-approved drugs act on GPCRs. We are actively pursuing several discovery programs to find peptides and small molecules directed against these GPCRs to develop as potential therapies.

GPCR
modulating agents

7171 Frederick-Banting
Saint-Laurent, Québec 
H4S 1Z9,  Canada

Finding hope by expanding the frontiers of therapy

Find Therapeutics © 2024. All Rights Reserved.